BACKGROUND: While laboratory data suggest that antidepressants may promote mammary tumor growth, there has been little research investigating whether antidepressant use after breast cancer diagnosis is associated with the risk of breast cancer recurrence. METHODS: We conducted a retrospective cohort study within Group Health, an integrated healthcare delivery system in Washington state. Women diagnosed with a first primary invasive, stage I, IIA, or IIB, unilateral breast carcinoma between 1990-1994 (aged>or=65 years) and 1996-1999 (aged>or=18 years) were eligible for the study (N=1306). Recurrence within 5-year of diagnosis was ascertained by medical chart review. We used the pharmacy database to identify antidepressant dispensings from Group Health pharmacies. We used multiple Cox regression to estimate the hazard ratio for recurrence and breast cancer mortality, comparing users and non-users of antidepressant medications. Results for recurrence were examined separately in users and non-users of tamoxifen. RESULTS: We did not observe an association between antidepressant use after breast cancer diagnosis and the risk of recurrence either in general (hazard ratio for any antidepressant use: 0.8; 95% confidence interval: 0.5-1.4) or for specific types of antidepressant medication. Risk of death from breast cancer did not differ between non-users and users of antidepressants. CONCLUSIONS: The results of this study suggest that women who use antidepressants after breast cancer diagnosis do not have an increased risk of recurrence or mortality.
BACKGROUND: While laboratory data suggest that antidepressants may promote mammary tumor growth, there has been little research investigating whether antidepressant use after breast cancer diagnosis is associated with the risk of breast cancer recurrence. METHODS: We conducted a retrospective cohort study within Group Health, an integrated healthcare delivery system in Washington state. Women diagnosed with a first primary invasive, stage I, IIA, or IIB, unilateral breast carcinoma between 1990-1994 (aged>or=65 years) and 1996-1999 (aged>or=18 years) were eligible for the study (N=1306). Recurrence within 5-year of diagnosis was ascertained by medical chart review. We used the pharmacy database to identify antidepressant dispensings from Group Health pharmacies. We used multiple Cox regression to estimate the hazard ratio for recurrence and breast cancer mortality, comparing users and non-users of antidepressant medications. Results for recurrence were examined separately in users and non-users of tamoxifen. RESULTS: We did not observe an association between antidepressant use after breast cancer diagnosis and the risk of recurrence either in general (hazard ratio for any antidepressant use: 0.8; 95% confidence interval: 0.5-1.4) or for specific types of antidepressant medication. Risk of death from breast cancer did not differ between non-users and users of antidepressants. CONCLUSIONS: The results of this study suggest that women who use antidepressants after breast cancer diagnosis do not have an increased risk of recurrence or mortality.
Authors: Mogens Groenvold; Morten Aagaard Petersen; Ellen Idler; Jakob Bue Bjorner; Peter M Fayers; Henning T Mouridsen Journal: Breast Cancer Res Treat Date: 2007-01-03 Impact factor: 4.872
Authors: Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Kathleen Meeske; Ashley Wilder Smith; Catherine M Alfano; Bonnie A McGregor; Anne McTiernan; Kathy B Baumgartner; Kathleen E Malone; Bryce B Reeve; Rachel Ballard-Barbash; Leslie Bernstein Journal: Qual Life Res Date: 2007-04-25 Impact factor: 4.147
Authors: Diana S M Buist; Laura Ichikawa; Marianne N Prout; Marianne Ulcickas Yood; Terry S Field; Cynthia Owusu; Ann M Geiger; Virginia P Quinn; Feifei Wei; Rebecca A Silliman Journal: J Clin Oncol Date: 2007-08-10 Impact factor: 44.544
Authors: Soe Soe Thwin; Kerri M Clough-Gorr; Maribet C McCarty; Timothy L Lash; Sharon H Alford; Diana S M Buist; Shelley M Enger; Terry S Field; Floyd Frost; Feifei Wei; Rebecca A Silliman Journal: BMC Med Res Methodol Date: 2007-06-18 Impact factor: 4.615
Authors: Jessica Chubak; Denise M Boudreau; Heidi S Wirtz; Barbara McKnight; Noel S Weiss Journal: J Natl Cancer Inst Date: 2013-08-12 Impact factor: 13.506
Authors: Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau Journal: Cancer Causes Control Date: 2015-10-30 Impact factor: 2.506
Authors: Heidi S Wirtz; Denise M Boudreau; Julie R Gralow; William E Barlow; Shelly Gray; Erin J A Bowles; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-01-10 Impact factor: 4.872
Authors: Brian L Sprague; Amy Trentham-Dietz; Hazel B Nichols; John M Hampton; Polly A Newcomb Journal: Breast Cancer Res Treat Date: 2010-04-02 Impact factor: 4.872
Authors: Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau Journal: Am J Epidemiol Date: 2017-04-15 Impact factor: 4.897
Authors: David S Carrell; Scott Halgrim; Diem-Thy Tran; Diana S M Buist; Jessica Chubak; Wendy W Chapman; Guergana Savova Journal: Am J Epidemiol Date: 2014-01-30 Impact factor: 4.897
Authors: Tracy Onega; Andrea Cook; Beth Kirlin; Xun Shi; Jennifer Alford-Teaster; Leah Tuzzio; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2011-05-07 Impact factor: 4.872
Authors: Catherine M Kelly; David N Juurlink; Tara Gomes; Minh Duong-Hua; Kathleen I Pritchard; Peter C Austin; Lawrence F Paszat Journal: BMJ Date: 2010-02-08